LVTX
Price:
$1.6
Market Cap:
$42.07M
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody...[Read more]
Industry
Biotechnology
IPO Date
2021-03-26
Stock Exchange
NASDAQ
Ticker
LVTX
According to LAVA Therapeutics N.V.’s latest financial reports and current stock price. The company's current Enterprise Value is 13.14M. This represents a change of -13.85% compared to the average of 15.26M of the last 4 quarters.
The mean historical Enterprise Value of LAVA Therapeutics N.V. over the last ten years is 113.69M. The current 13.14M Enterprise Value has changed 1.06% with respect to the historical average. Over the past ten years (40 quarters), LVTX's Enterprise Value was at its highest in in the December 2020 quarter at 350.57M. The Enterprise Value was at its lowest in in the March 2021 quarter at -156402799.38.
Average
113.69M
Median
4.32M
Minimum
-36828221.50
Maximum
348.12M
Discovering the peaks and valleys of LAVA Therapeutics N.V. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 35.46%
Maximum Annual Enterprise Value = 348.12M
Minimum Annual Increase = -204.11%
Minimum Annual Enterprise Value = -36828221.50
Year | Enterprise Value | Change |
---|---|---|
2023 | 4.32M | -204.11% |
2022 | -4148982.50 | -88.73% |
2021 | -36828221.50 | -110.58% |
2020 | 348.12M | 35.46% |
The current Enterprise Value of LAVA Therapeutics N.V. (LVTX) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-12219255.17
5-year avg
113.69M
10-year avg
113.69M
LAVA Therapeutics N.V.’s Enterprise Value is less than Anebulo Pharmaceuticals, Inc. (36.46M), less than PMV Pharmaceuticals, Inc. (47.77M), less than Miromatrix Medical Inc. (90.06M), less than ZIVO Bioscience, Inc. (73.95M), greater than Bionomics Limited (-2112255.00), less than Edgewise Therapeutics, Inc. (3.01B), less than Ikena Oncology, Inc. (45.73M), less than Design Therapeutics, Inc. (290.40M), greater than Xilio Therapeutics, Inc. (-13633399.00), less than Eliem Therapeutics, Inc. (119.64M), less than Aerovate Therapeutics, Inc. (46.23M), less than Adagene Inc. (22.22M), less than Acrivon Therapeutics, Inc. Common Stock (163.47M), less than Rezolute, Inc. (276.11M), greater than AN2 Therapeutics, Inc. (6.48M), less than Generation Bio Co. (163.63M), greater than Kronos Bio, Inc. (5.32M), less than Erasca, Inc. (747.42M), less than C4 Therapeutics, Inc. (307.45M), greater than Neoleukin Therapeutics, Inc. (-6333315.00), less than Instil Bio, Inc. (165.40M), greater than Achilles Therapeutics plc (-38865958.00), greater than NextCure, Inc. (11.01M), less than Assembly Biosciences, Inc. (68.59M),
Company | Enterprise Value | Market cap |
---|---|---|
36.46M | $37.86M | |
47.77M | $83.31M | |
90.06M | $92.95M | |
73.95M | $74.08M | |
-2112255.00 | $5.75M | |
3.01B | $3.05B | |
45.73M | $82.52M | |
290.40M | $318.21M | |
-13633399.00 | $39.21M | |
119.64M | $342.68M | |
46.23M | $76.81M | |
22.22M | $97.11M | |
163.47M | $202.87M | |
276.11M | $284.50M | |
6.48M | $39.99M | |
163.63M | $91.51M | |
5.32M | $54.49M | |
747.42M | $763.36M | |
307.45M | $300.00M | |
-6333315.00 | $8.20M | |
165.40M | $170.65M | |
-38865958.00 | $43.57M | |
11.01M | $33.33M | |
68.59M | $95.60M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like LAVA Therapeutics N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like LAVA Therapeutics N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is LAVA Therapeutics N.V.'s Enterprise Value?
What is the highest Enterprise Value for LAVA Therapeutics N.V. (LVTX)?
What is the 3-year average Enterprise Value for LAVA Therapeutics N.V. (LVTX)?
What is the 5-year average Enterprise Value for LAVA Therapeutics N.V. (LVTX)?
How does the current Enterprise Value for LAVA Therapeutics N.V. (LVTX) compare to its historical average?